Abstract | PURPOSE: METHODS: In this prospective, randomized, investigator-masked, comparative clinical trial, patients with mild-to-moderate noninfectious AAU were assigned randomly to receive either hourly nonpreserved methylprednisolone 1% (group A) or preserved prednisolone 1% (group B) eye drops followed by a 2-week tapering regimen. Anterior chamber cells and flare were clinically evaluated for the objective comparison of the antiinflammatory effect. The main outcome measure was the percentage of patients with a resolution of inflammation (anterior chamber cells <1+) on day 14. Ocular surface toxicity was assessed by means of the corneal fluorescein staining score, tear breakup time, Schirmer I test, and questionnaire-based grading of ocular discomfort parameters. RESULTS: Seventy-two eyes of 68 patients were studied, of which 38 eyes were enrolled in group A and 34 eyes were enrolled in group B. On day 14, 76.3% of the patients in group A had resolution of inflammation compared with 70.6% of the patients in group B, proving noninferiority (χ = 0.303, P = 0.582). The mean anterior chamber cell grade reduction for patients in group A was similar to that in group B (2.52 vs. 2.86, respectively; P = 0.92). Group A patients showed significantly lower corneal fluorescein staining scores (P < 0.001) and reported milder subjective ocular discomfort (0.55 vs. 1.43, P = 0.01) as compared with group B. CONCLUSIONS: Both preparations demonstrated equal antiinflammatory effects for the treatment of AAU. Nonpreserved methylprednisolone eye drops exhibited a significantly lower ocular surface toxicity profile and milder subjective discomfort when compared with that exhibited by preserved prednisolone.
|
Authors | Alireza Hedayatfar, Hassan Hashemi, Soheila Asgari, Soon-Phaik Chee |
Journal | Cornea
(Cornea)
Vol. 33
Issue 4
Pg. 366-72
(Apr 2014)
ISSN: 1536-4798 [Electronic] United States |
PMID | 24351572
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Glucocorticoids
- Ophthalmic Solutions
- Preservatives, Pharmaceutical
- Methylprednisolone Hemisuccinate
- prednisolone acetate
- Prednisolone
|
Topics |
- Acute Disease
- Administration, Topical
- Adolescent
- Adult
- Cornea
(drug effects)
- Double-Blind Method
- Eyelids
(drug effects)
- Female
- Fluorophotometry
- Glucocorticoids
(therapeutic use)
- Humans
- Intraocular Pressure
(drug effects)
- Male
- Methylprednisolone Hemisuccinate
(adverse effects, therapeutic use)
- Middle Aged
- Ophthalmic Solutions
- Prednisolone
(adverse effects, analogs & derivatives, therapeutic use)
- Preservatives, Pharmaceutical
(adverse effects, therapeutic use)
- Prospective Studies
- Surveys and Questionnaires
- Tears
(physiology)
- Treatment Outcome
- Uveitis, Anterior
(drug therapy)
- Young Adult
|